Trial reportJournal of the American Society of Nephrology : JASN2011
Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis.
Trial report in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Effectiveness of different antibiotic lock solutions on catheter-related infections of hemodialysis patients: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.The Cochrane database of systematic reviews · 2022Pooled it
- Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis.The Cochrane database of systematic reviews · 2018Pooled it
- Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.The Cochrane database of systematic reviews · 2016Pooled it
- Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol.Antimicrobial agents and chemotherapy · 2016Trial
- Timing of Antimicrobial Lock Replacement for Gram-Positive Port Infections: Results of a Randomized Trial.Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Lock Therapy in Clinical Practice: A Scoping Review.Microorganisms · 2025Review
- Antibiotic lock solutions as adjunct therapy for catheter-related blood stream infections in pediatric hemodialysis patients.Frontiers in pediatrics · 2024Review
- Bacteremia and Mortality among Patients with Nontunneled and Tunneled Catheters for Hemodialysis.International journal of nephrology · 2024Article
- Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review.Renal failure · 2022Review
- Pre-Emptive Antimicrobial Locks Decrease Long-Term Catheter-Related Bloodstream Infections in Hemodialysis Patients.Antibiotics (Basel, Switzerland) · 2022Article
- Central Venous Catheters for Hemodialysis-the Myth and the Evidence.Kidney international reports · 2021Review
- Novel colistin-EDTA combination for successful eradication of colistin-resistant Klebsiella pneumoniae catheter-related biofilm infections.Scientific reports · 2021Article
- Does antimicrobial lock solution reduce catheter-related infections in hemodialysis patients with central venous catheters? A Bayesian network meta-analysis.International urology and nephrology · 2017Review
- The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors.Journal of the American Society of Nephrology : JASN · 2017Observational
- Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials.International journal of clinical and experimental medicine · 2015Article
- Temporary hemodialysis catheters: recent advances.Kidney international · 2014Review
- Antibiotic lock therapy: review of technique and logistical challenges.Infection and drug resistance · 2014Review
- N-acetylcysteine lock solution prevents catheter-associated bacteremia in rabbits.The International journal of artificial organs · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is growing concern about the development of antibacterial resistance with the use of antibiotics in catheter lock solutions. The use of an antibiotic that is not usually used to treat other serious infections may be an alternative that may reduce the clinical impact should resistance develop. We conducted a randomized controlled trial to compare a solution of minocycline and EDTA with the conventional unfractionated heparin for the prevention of catheter-related bacteremia in hemodialysis patients during a period of 90 d. The study included 204 incident catheters (27.8% tunneled); 14 catheters were excluded because of early dysfunction and 3 because of protocol violations. We observed catheter-related bacteremia in 19 patients in the heparin group (4.3 per 1000 catheter-days) and in 5 patients in the minocycline-EDTA group (1.1 per 1000 catheter-days; P = 0.005). We did not detect a significant difference in the rate of catheter removal for dysfunction. Catheter-related bacteremia-free survival was significantly higher in the minocycline-EDTA group than in the heparin group (P = 0.005). In conclusion, a minocycline-EDTA catheter lock solution is effective in the prevention of catheter-related bacteremia in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.